Fairley C K, Begg N, Borrow R, Fox A J, Jones D M, Cartwright K
Public Health Laboratory Service, Communicable Disease Surveillance Centre, London, United Kingdom.
J Infect Dis. 1996 Dec;174(6):1360-3. doi: 10.1093/infdis/174.6.1360.
The reactogenicity and immunogenicity of a serogroup A and C meningococcal polysaccharide-CRM197 conjugate vaccine was evaluated in 58 infants who received three doses at 2, 3, and 4 months of age. The conjugate vaccine produced few systemic side effects, and local reactions were significantly less common than those produced by the routine vaccinations. The prevaccination geometric mean titers (GMTs) of A and C polysaccharide antibodies were, respectively, 2.8 and 0.6 microg/mL, rising to 21.5 and 38.5 microg/mL by 1 month after the third dose (age 5 months) and falling to 3.1 and 2.2 mircog/mL by 14 months of age. Prevaccination serum bactericidal titers against 2 serogroup C meningococci strains were <1/4 in 49 of 52 infants, rising to a GMT of 1/3082 at 1 month after the third dose and falling by age 14 months to a GMT of 1/10. Thus, this meningococcal conjugate vaccine proved to be safe and immunogenic, inducing high levels of anti-C polysaccharide antibodies that were bactericidal in young infants.
对58名在2、3、4月龄时接种3剂A群和C群脑膜炎球菌多糖-CRM197结合疫苗的婴儿，评估了该疫苗的反应原性和免疫原性。该结合疫苗产生的全身副作用较少，且局部反应明显少于常规疫苗接种所产生的反应。接种疫苗前A和C多糖抗体的几何平均滴度（GMT）分别为2.8和0.6μg/mL，在第三剂接种后1个月（5月龄）时升至21.5和38.5μg/mL，到14月龄时降至3.1和2.2μg/mL。接种疫苗前，52名婴儿中有49名针对2株C群脑膜炎球菌菌株的血清杀菌滴度<1/4，在第三剂接种后1个月时GMT升至1/3082，到14月龄时降至GMT为1/10。因此，这种脑膜炎球菌结合疫苗被证明是安全且具有免疫原性的，能在幼儿中诱导产生高水平的具有杀菌作用的抗C多糖抗体。
